S

Shanghai MicroPort EP Medtech Co Ltd
SSE:688351

Watchlist Manager
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
Watchlist
Price: 20.15 CNY 0.85%
Market Cap: 9.5B CNY
Have any thoughts about
Shanghai MicroPort EP Medtech Co Ltd?
Write Note

Shanghai MicroPort EP Medtech Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicroPort EP Medtech Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
Accounts Payable
ÂĄ37.4m
CAGR 3-Years
99%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Accounts Payable
ÂĄ42.7m
CAGR 3-Years
72%
CAGR 5-Years
44%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Accounts Payable
ÂĄ1.3B
CAGR 3-Years
11%
CAGR 5-Years
23%
CAGR 10-Years
17%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Accounts Payable
ÂĄ3.9B
CAGR 3-Years
29%
CAGR 5-Years
20%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Accounts Payable
ÂĄ133.1m
CAGR 3-Years
33%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Accounts Payable
ÂĄ1.6B
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicroPort EP Medtech Co Ltd
Glance View

Market Cap
9.5B CNY
Industry
Health Care

Shanghai MicroPort EP Medtech Co. Ltd. has carved a distinct niche for itself within the rapidly evolving medical device industry, primarily focusing on electrophysiology. This innovative field deals with diagnosing and treating arrhythmias—irregular heartbeats that affect countless individuals globally. MicroPort EP's flagship products include advanced catheter-based systems and cardiac mapping technologies that physicians utilize to pinpoint and correct these heart rhythm disorders. Their solutions are intricately designed to improve the accuracy and effectiveness of ablation procedures, allowing for non-invasive interventions that can significantly enhance patient outcomes. By capitalizing on the increasing prevalence of cardiovascular ailments and the push towards less invasive medical treatments, the company has positioned itself as a pivotal player in the healthcare sector, gaining a competitive edge with its sophisticated R&D capabilities and product innovation. The company's revenue model revolves around the development, manufacturing, and sales of its proprietary electrophysiology devices. By investing heavily in research and development, MicroPort EP continually advances its product offerings, aiming to stay ahead of its competitors and meet the growing demands of healthcare professionals and patients alike. Sales are driven both domestically, within China's burgeoning healthcare market, and internationally, tapping into the global need for cutting-edge cardiac solutions. The integration of technology and healthcare expertise underscores their commitment to quality and innovation, ensuring a sustainable model as they advance in this niche sector. Ultimately, their financial performance reflects a strategic alignment with health trends and technological progress, allowing them to capture value in a market poised for significant growth.

Intrinsic Value
7.2 CNY
Overvaluation 64%
Intrinsic Value
Price
S

See Also

What is Shanghai MicroPort EP Medtech Co Ltd's Accounts Payable?
Accounts Payable
37.4m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicroPort EP Medtech Co Ltd's Accounts Payable amounts to 37.4m CNY.

What is Shanghai MicroPort EP Medtech Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
99%

Over the last year, the Accounts Payable growth was 72%. The average annual Accounts Payable growth rates for Shanghai MicroPort EP Medtech Co Ltd have been 99% over the past three years .

Back to Top